Eli Lilly and
743.02
-54.46 (-6.83%)
At close: Jan 14, 2025, 3:59 PM
747.47
0.60%
Pre-market Jan 15, 2025, 06:39 AM EST
undefined%
Bid 741.38
Market Cap 705.36B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 9.25
PE Ratio (ttm) 80.33
Forward PE n/a
Analyst Buy
Ask 751
Volume 9,444,635
Avg. Volume (20D) 3,891,521
Open 784.23
Previous Close 797.48
Day's Range 729.00 - 784.23
52-Week Range 612.70 - 972.53
Beta undefined

About LLY

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer ...

Sector Healthcare
IPO Date Jun 1, 1972
Employees 43,000
Stock Exchange NYSE
Ticker Symbol LLY

Analyst Forecast

According to 27 analyst ratings, the average rating for LLY stock is "Buy." The 12-month stock price forecast is $1008, which is an increase of 35.66% from the latest price.

Buy 66.67%
Hold 7.41%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Eli Lilly and is scheduled to release its earnings on Feb 6, 2025, before market opens.
Analysts project revenue of $13.95B, reflecting a 49.15% YoY growth and earnings per share of 5.42, making a 117.67% increase YoY.
1 day ago · Source
-6.59%
Eli Lily shares are trading lower after the compan... Unlock content with Pro Subscription
3 weeks ago · Source
+3.71%
Ely Lilly shares are trading higher after the FDA approved the company's Zepbound, a weight loss drug designed to treat moderate-to-severe obstructive sleep apnea in adults with obesity.